Standardization of tumor budding assessment was achieved by the International Tumor Budding Consensus Conference (ITBCC) recommendations in 2016: identification of the budding hotspot (measuring 0.785 mm2) at the invasive front of the tumor and counting of the number of buds results in a score that can be classified as Bd1 (0–4 buds), Bd2 (5–9 buds) or Bd3 (10 or more buds)9. The gene discussed is DEFB1; the disease is neoplasm.